TLIK.F Arzneiwerk AG (XETRA) up 50% pre-market 19 Feb 2026: 0.51 EUR target

TLIK.F stock jumped 50.38% in pre-market trade on XETRA on 19 Feb 2026, trading at €0.39 after an open at €0.39. The move lifted volume to 958 shares versus an average 694. Investors are pricing a short-term re-rating after thin liquidity pushed intraday volatility. We track valuation, technicals, and Meyka AI forecasts to explain the spike and next levels for Arzneiwerk AG VIDA in Germany.

TLIK.F stock: pre-market price action and drivers

The main fact is a €0.132 one-day gain from the previous close of €0.26, giving a live price of €0.39. Volume rose to 958, equal to a relative volume of 1.38, suggesting the move is real but still thin.

Market participants point to low free float and small market cap of €2,455,967.00 as amplification factors. The company lists on XETRA and operates in Healthcare distribution, which can draw event-driven interest for rare-drug suppliers.

Valuation snapshot and TLIK.F stock fundamentals

Arzneiwerk AG VIDA shows a trailing EPS of -€0.11 and a reported PE of -3.58, reflecting losses. Price averages sit at €0.31 (50-day) and €0.36 (200-day), placing current price slightly above the 200-day average.

Key balance metrics are weak: cash per share €0.00, current ratio 0.04, and negative operating cash flow per share -€0.35. These figures highlight liquidity risk despite the share spike. Year high is €0.69 and year low €0.00, showing wide range for the stock.

Technicals, volume and trading signals for TLIK.F stock

Momentum indicators show RSI 47.61 and ADX 33.43, indicating a developing trend but no clear overbought signal yet. MFI reads 94.53, which registers as overbought on intraday flow.

Price sits at the upper Bollinger band €0.37 and Keltner upper €0.39, supporting the pre-market push. On balance volume (OBV) is 12,923, consistent with recent buying. Given low average volume, technical signals can flip quickly.

Meyka AI grade, forecast and TLIK.F stock price targets

Meyka AI rates TLIK.F with a score of 62.91 out of 100 — Grade B, suggestion HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus.

Meyka AI’s forecast model projects a monthly price of €0.27 and a quarterly price of €0.51. Compared to the current €0.39, the quarterly forecast implies an upside of 29.44%, while the monthly figure suggests downside of -31.48%. Forecasts are model-based projections and not guarantees.

Sector context and risk factors for TLIK.F stock

Arzneiwerk sits in Healthcare, where the sector average PE is 30.65 and average current ratio is 2.84. TLIK.F’s metrics are well below these norms, underlining structural weakness versus peers.

Major risks are limited liquidity, negative cash flow, and small employee base of 20. Opportunities include niche supply deals for rare medicines that could boost revenue per share if secured. Regulatory or contract news would likely drive the next moves.

Final Thoughts

TLIK.F stock’s 50.38% pre-market jump on 19 Feb 2026 is a clear short-term price event in a thinly traded Healthcare small cap listed on XETRA in Germany. The share trades at €0.39, with market cap €2,455,967.00, EPS -€0.11, and volume 958. Technicals show a rising trend but mixed momentum and overbought money flow. Meyka AI’s models show a near-term downside to €0.27 and a quarterly upside to €0.51, implying -31.48% and +29.44% moves versus the current price respectively. Our conclusion: the stock is event-driven and volatile. Use tight risk controls, expect fast reversals, and monitor company announcements and trade volume closely. For an internal view and live quotes see Meyka’s stock page: https://meyka.ai/stocks/TLIK.F. External company details are available at the Arzneiwerk site and profile image source Arzneiwerk AG VIDA and FinancialModelingPrep. Forecasts are model-based projections and not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.